IRIS UniCatt

De Cristofaro, Raimondo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.739
AS - Asia 5.538
EU - Europa 5.175
SA - Sud America 1.097
Continente sconosciuto - Info sul continente non disponibili 200
AF - Africa 168
OC - Oceania 17
Totale 20.934
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.422
SG - Singapore 2.448
DE - Germania 1.514
CN - Cina 1.287
BR - Brasile 881
SE - Svezia 816
IT - Italia 684
VN - Vietnam 519
UA - Ucraina 470
FR - Francia 426
GB - Regno Unito 274
IE - Irlanda 235
IN - India 229
FI - Finlandia 181
JP - Giappone 173
RU - Federazione Russa 170
ID - Indonesia 167
PL - Polonia 163
BD - Bangladesh 157
CA - Canada 144
HK - Hong Kong 127
AR - Argentina 82
TR - Turchia 75
IQ - Iraq 63
MX - Messico 58
NL - Olanda 52
ZA - Sudafrica 47
KR - Corea 39
EC - Ecuador 34
IL - Israele 29
CO - Colombia 28
BE - Belgio 27
VE - Venezuela 25
ES - Italia 24
PK - Pakistan 24
PH - Filippine 23
AT - Austria 21
IR - Iran 21
SA - Arabia Saudita 21
UZ - Uzbekistan 20
HN - Honduras 19
SC - Seychelles 19
JM - Giamaica 18
MA - Marocco 18
LT - Lituania 17
AU - Australia 16
CL - Cile 16
CR - Costa Rica 16
KE - Kenya 16
TT - Trinidad e Tobago 16
CI - Costa d'Avorio 14
EG - Egitto 14
MY - Malesia 14
RO - Romania 14
TN - Tunisia 13
AE - Emirati Arabi Uniti 12
CZ - Repubblica Ceca 12
NP - Nepal 11
PY - Paraguay 11
DZ - Algeria 10
UY - Uruguay 10
JO - Giordania 9
KZ - Kazakistan 9
MK - Macedonia 8
NI - Nicaragua 8
OM - Oman 8
AL - Albania 7
CH - Svizzera 7
LV - Lettonia 7
PT - Portogallo 7
BH - Bahrain 6
CW - ???statistics.table.value.countryCode.CW??? 6
GT - Guatemala 6
HU - Ungheria 6
KW - Kuwait 6
PR - Porto Rico 6
SN - Senegal 6
SV - El Salvador 6
BO - Bolivia 5
DO - Repubblica Dominicana 5
KG - Kirghizistan 5
NO - Norvegia 5
PE - Perù 5
PS - Palestinian Territory 5
AM - Armenia 4
AZ - Azerbaigian 4
ET - Etiopia 4
EU - Europa 4
GR - Grecia 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BA - Bosnia-Erzegovina 3
BB - Barbados 3
BG - Bulgaria 3
GP - Guadalupe 3
HR - Croazia 3
LU - Lussemburgo 3
PA - Panama 3
RS - Serbia 3
SY - Repubblica araba siriana 3
Totale 20.708
Salva come PNG Salva come JPEG
Città #
Singapore 1.257
Ashburn 1.255
San Jose 874
Chandler 657
Jacksonville 263
Beijing 245
Dublin 226
San Mateo 212
Los Angeles 172
New York 162
Ho Chi Minh City 161
Nanjing 161
Tokyo 157
Council Bluffs 156
Wilmington 149
Jakarta 146
Lauterbourg 146
Warsaw 135
Hefei 130
Hanoi 128
Milan 124
Chicago 114
Ann Arbor 112
St Louis 110
Santa Clara 107
Hong Kong 106
Boston 102
Woodbridge 99
Houston 91
Dearborn 89
Munich 89
Dallas 83
Frankfurt am Main 81
Moscow 81
Fairfield 78
Rome 75
Seattle 73
São Paulo 72
Lawrence 71
Pune 71
Redwood City 71
North Bergen 68
Nürnberg 65
Princeton 59
Helsinki 57
Phoenix 54
Buffalo 53
Cattolica 53
Nanchang 52
Marseille 46
Redmond 45
London 43
Atlanta 40
The Dalles 40
Boardman 37
Izmir 36
Rio de Janeiro 35
Orem 34
Seoul 33
University Park 33
Bremen 32
Kent 32
Brooklyn 31
Hangzhou 31
Toronto 30
Da Nang 29
Augusta 28
Paris 28
Kunming 27
Tianjin 27
Nuremberg 26
Mexico City 25
Mountain View 25
San Francisco 25
Baghdad 24
Montreal 24
Turku 24
Brussels 23
Denver 23
Johannesburg 23
Norwalk 23
Changsha 22
Hyderabad 22
Naples 22
Philadelphia 22
Detroit 21
Shanghai 21
Shenyang 21
Amsterdam 19
Brasília 19
Zhengzhou 19
Chennai 18
Guangzhou 18
Haiphong 18
Bareggio 17
Hebei 17
Jiaxing 17
San Diego 17
Cambridge 16
Tashkent 16
Totale 10.496
Salva come PNG Salva come JPEG
Nome #
The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitus. 350
Qualitative and quantitative modifications of von willebrand factor in patients with essential thrombocythemia and controlled platelet count 346
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment 344
The Type 2b P.R1306w Natural Mutation Of Von Willebrand Factor Dramatically Enhances The Multimer Sensitivity To Shear Stress 329
Pathogenesis Of Portal Vein Thrombosis In Liver Cirrhosis: The Role of the ADAMTS13/VWF Unbalance 306
Novel path to IL-6 trans-signaling through thrombin-induced soluble IL-6 receptor release by platelets 240
Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study 220
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development 208
Kinetic study of von Willebrand factor self-aggregation induced by ristocetin 199
Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice. 197
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 193
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy 190
Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D9D3 and D4 domains 187
Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover study 184
Pseudo-acquired vWD in essential thrombocythemia: the role of platelets 184
Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13. A new prothrombotic mechanism associated with oxidative stress 179
β2-Glycoprotein I Binds Thrombin and Selectively Inhibits the Enzyme Procoagulant Functions 179
Effect of fibrinogen concentration on the velocity of platelet aggregation. 178
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 175
The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical and in silico study 165
Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study 164
Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells 164
MORE EARLY BLEEDS ASSOCIATED WITH HIGH BASELINE DIRECT ORAL ANTICOAGULANT LEVELS IN ATRIAL FIBRILLATION: THE MAS STUDY 163
Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation 162
Immune toilerance by intermittent factor VIII boluses in two hemophilia A patients 161
Evaluation of the thiobarbituric acid test (TBA test) properties for the determination of glycosylated hemoglobins by comparison with chromatography and isoelectrofocusing. 161
Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle 160
Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from adamts-13 160
high performance liquid chromatography in protein sequence determination. 160
Congenital prothrombin deficiency: an update 160
An old drug for a new application: carbazochrome-sodium-sulfonate in HHT 160
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma 160
Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects. 159
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 159
Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients? 159
Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects 156
Diagnosis and management of cerebral venous sinus thrombosis in children: a single-center retrospective analysis 156
Direct oral anticoagulants and therapeutic adherence: do not let your guard down 155
Detection of Platelet-Activating Antibodies Associated with Vaccine-Induced Thrombotic Thrombocytopenia by Flow Cytometry: An Italian Experience 152
Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. 149
Structural and funtional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib 148
Ristocetin-induced self-aggregation of von Willebrand factor. 146
Hexopeptidase high performance liquid chromatography (HPLC) mapping and is application to peptide sequence strategies. 146
Hemophilia A and von Willebrand deficiency: therapeutic implications 144
PURIFICATION OF THE ISOLATED BETA-CHAIN OF ADULT HUMAN-HEMOGLOBIN FROM ITS POST-TRANSLATIONAL MODIFICATION 143
Mechanochemistry of von Willebrand factor 143
From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19 143
Aims: The ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of Edoxaban administered via PEG in patients with atrial fibrillation and a clinical indication for a long-term anticoagulation. Design: In this prospective, single-centre observational study, 12 PEG-treated patients with indication to anticoagulation will receive edoxaban via PEG and will be followed up to 6 months. Plasma antifactor Xa activity and edoxaban concentrations will be assessed. Thromboembolic (ischaemic stroke, systemic embolism, venous thromboembolism) and bleeding events (Bleeding Academic Research Consortium and Thrombolysis in Myocardial Infarction) will be recorded at 1 and 6 months. Preliminary results: A retrospective analysis of five atrial fibrillation cases undergoing PEG implantation at our Institution who received edoxaban via PEG showed plasma anti-FXa levels at a steady state of 146 ± 15 ng/ml, without major adverse event at a mean follow-up of 6 months. Conclusion: ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. 142
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma 140
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy 140
Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and the alpha-granule content in the patient and four relatives 136
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 134
Congenital prothrombin deficiency 134
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study 133
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study 132
Effects of coagulation factors on bone cells and consequences of their absence in haemophilia a patients 131
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients 131
Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. 131
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response 130
Proteolytic Processing of Von Willebrand Factor by Adamts13 and Leukocyte Proteases 130
High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism 128
Another family with IGPS 127
Inherited macrothrombocytopenia with distinctive platelet ultrastructural and functional features 126
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 126
β2 -Glycoprotein I binds to thrombin and selectively inhibits the enzyme procoagulant functions 125
Increased platelet-fibrinogen affinity in patients with myeloproliferative disorders. 124
SPONTANEOUS DEEP HEMATOMAS IN 2 PATIENTS WITH MYELOFIBROSIS - EVIDENCE OF PLATELET MEMBRANE GLYCOPROTEIN MODIFICATIONS 124
Extended coagulation profile of children with Long Covid: a prospective study 123
Thrombin-thrombomodulin interaction: energetics and potential role of water as an allosteric effector. 123
Biochemical properties of indoleamine 2,3-dioxygenase: from structure to optimized design of inhibitors 123
Design organization and clinical processes around patient characteristics: Evidence from a multiple case study of Hemophilia 122
The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation. 122
The effect of shear stress on protein conformation: Physical forces operating on biochemical systems: The case of von Willebrand factor. 122
Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia 122
Homocysteinemia is inversely correlated with platelet count and inversely correlated with sE-and sP-selectin levels in females homozygous for C677T methylenetetrahydrofolate reductase 120
Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban 120
ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study 120
Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies 119
Allosteric equilibria in the binding reaction of fibrinogen to platelets. 119
Oral Squamous Cell Carcinoma-Associated Thrombosis: What Evidence? 118
Thrombin interaction with platelet GpIB: role of the heparin binding domain. 117
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 117
Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini‐Delphi Consensus 117
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study 116
Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients 116
Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure 116
Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA 116
Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects 115
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 114
Wiskott-Aldrich syndrome: report of an autosomal dominant variant 111
Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey 111
Immune and Hereditary Thrombotic Thrombocytopenic Purpura: Can ADAMTS13 Deficiency Alone Explain the Different Clinical Phenotypes? 110
Binding of human alpha-thrombin to platelet GpIb: energetics and functional effects. 110
KINETIC ASPECTS OF RELEASE OF FIBRINOPEPTIDES AP AND AY BY HUMAN ALPHA-THROMBIN 110
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 110
Apixaban Interacts with Haemoglobin: Effects on Its Plasma Levels 109
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study 107
The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms 107
Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding 106
The linkage between binding of the C-terminal domain of hirudin and amidase activity in human alpha-thrombin 106
Totale 15.184
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.033
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.033
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022841 0 0 0 0 64 35 34 173 60 54 206 215
2022/20231.973 264 318 165 259 155 233 80 171 230 26 56 16
2023/20241.163 41 316 30 78 49 203 66 61 17 39 102 161
2024/20252.597 58 42 197 98 191 89 59 121 419 317 554 452
2025/20267.167 1.071 306 452 718 1.068 352 1.286 357 443 567 304 243
2026/20272.715 228 418 507 1.357 205 0 0 0 0 0 0 0
Totale 20.934